尽管面临经济挑战, 癌症基因组学公司Personalis获得"买入"评级, 目标价为7.00美元. Personalis, a cancer genomics firm, receives a "Buy" rating with a $7.00 target price despite financial challenges.

开发先进癌症基因组测试的公司Personalis获得了Nidham & Company LLC的"购买"评级, 目标价为7.00美元. Personalis, a company that develops advanced cancer genomic tests, has received a "Buy" rating from Needham & Company LLC with a target price of $7.00. 分析员预测今年的EPS为 - 1.4 EPS。 Analysts forecast a -1.4 EPS for this year. 该公司报告说,近期的Q1 EPS为0.23美元,击打估计数为0.09美元。 The company reported a recent Q1 EPS of ($0.23), beating estimates by $0.09. 个人拥有负净利润和股本回报率,机构投资者拥有61.91%的股票。 Personalis has a negative net margin and return on equity, with institutional investors owning 61.91% of the stock. 协商一致目标价格为7.80美元。 The consensus target price is $7.80.